2Nishimura C, Saito T, Tanimoto T. High levels of erythroeyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia, 1994, 37: 328-330.
3Ellis EA, Guberski DL, Hutson B, et al. Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat. Nitric Oxide, 2002, 6:295-304.
4Hanmes HP, Alt A, Niwa T, et al. Diferential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabet ologia, 1999,42 : 728-736.
5Handa JT, Verzijl N, Matsunaga H, et al. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. lnvest Ophthalmol Vis Sci,1999,40:775-779.
6Chibber R, Molinatti PA, Rosatto N, et al. Toxic action of advanced glycation end products on cultured retinal capilary pericytes and endothelial cells..relevance to diabetic retinopathy. Diabetologia, 1997,40 :156-164.
7Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol, 2002,86:363-365.
8Miyahara S, Kiryu J, Yamashiro K, et al. Simvastatin inhibits leukoeyte aeeumulation and vaseular permeability in the retinas of rats with streptozotoein-indueed diabetes. Am J Pathol, 2004,164:1697- 1706.
9Joussen AM,Poulaki V, Le ML, et al. The central role for inflammation in the pathogenesis of diabetic retinopathy. FASEBJ, 2004,18:1450-1452.
10Barber AJ. A new view of diabetic retinopathy:a neurodegenerative disease of the eye. Progress in neuropsychopharmacology & biological psychiatry, 2003 , 27, 283- 290.
